Minaris Advanced Therapies at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Minaris Advanced Therapies brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on raising viral vector yield and quality. Topics include silencing the cargo gene during lentiviral production and handling toxic payload expression in AAV manufacture using plasmid transfection.
| Organization | ESGCT 2026 Attendance |
|---|---|
Minaris Advanced Therapies Philadelphia, PA | |
Contract development, manufacturing and testing partner for cell and gene therapies, with sites in the US, Germany, the UK and Japan. | Poster Wed Oct 28 1:30pm–3:30pm Selective cargo gene silencing enhances lentiviral vector manufacturing efficiency and product quality. Poster Thu Oct 29 2:00pm–4:00pm Addressing toxic payload expression in Adeno-Associated Virus production using plasmid transfection and TESSA® |
Instantly find 20 buyers from Minaris Advanced Therapies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction